Study ID: Novartis CLGX818AUS03 Signature
Title:

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors

Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list